Clinical Trials Logo

Clinical Trial Summary

Thi is a prospective and low-intervention clinical trial. We propose to design a panel of "core" genetic alterations by sequencing Cerebral Spinal Fluid (CSF) DNA in patients with confirmed or suspicious Primary Central Neurvous System Lymphoma (PCNSL) with the aim to improve diagnostic sensitivity, response assessment and monitoring early CNS relapse in routine practice. Enrolled patients will receive conventional treatments according to well-established international guidelines, DNA assessments will not influence the treatment choices.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05036564
Study type Interventional
Source IRCCS San Raffaele
Contact Andrés J.M. Ferreri, MD
Phone 02 2643 7649
Email [email protected]
Status Recruiting
Phase N/A
Start date October 16, 2020
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03569995 - [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04627753 - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. Phase 2
Recruiting NCT04073147 - Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma Phase 1
Recruiting NCT04443829 - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma Phase 1
Recruiting NCT04006561 - Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Suspended NCT04656431 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma Phase 1
Recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT02934204 - Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Phase 2
Recruiting NCT04134117 - Tisagenlecleucel In Primary CNS Lymphoma Phase 1
Withdrawn NCT03212807 - Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Phase 2